Cashu | Summary

DJI

+0.53%

SPX

+0.32%

IXIC

+0.25%

FTSE

+0.44%

N225

+0.60%

AXJO

+0.90%

HomeWatchlistNewsSignalsPicks

Stocks

0.00 (0.00%)

0.000

USD

At close at --,----

Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.

Company

About Us
Careers
Blog
News

Help & Support

Help Center
Contact Us
Pro Support

Legal

Instagram YouTube

HomeWatchlistNewsSignalsPicks

DJI

+0.53%

SPX

+0.32%

IXIC

+0.25%

FTSE

+0.44%

N225

+0.60%

AXJO

+0.90%

HomeWatchlistNewsSignalsPicks

Join our newsletter to keep up to date with us!

Stocks

0.00 (0.00%)

0.000

USD

At close at --,----

Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.

Company

About Us
Careers
Blog
News

Help & Support

Help Center
Contact Us
Pro Support

Legal

Instagram YouTube

Join our newsletter to keep up to date with us!

Overview

Loading chart...

About

What does NTLA do?

Intellia Therapeutics, based in Cambridge, Massachusetts, develops CRISPR/Cas9-based therapeutics for high unmet medical needs, including treatments for ATTR amyloidosis and hereditary angioedema. The company went public on May 6, 2016.

Sector

💻 Health Care

IPO

CEO

Employees

Headquarters

Massachusetts, USA

Website

http://www.intelliatx.com

Key Stats

Market Cap

1.24B

Dividend Yield

0.00%

P/E Ratio

-2.35

EPS

-5.24

Revenue

57.88M

Avg. Volume

3.16M

Recently from Cashu

Cashu

Intellia Therapeutics and KalVista: Advancements in Hereditary Angioedema Treatment with KALV Ekterly

7 days ago

Cashu

Intellia Therapeutics: KalVista Pharmaceuticals Launches KALV Ekterly for Hereditary Angioedema Treatment

9 days ago

Cashu

Intellia Therapeutics Under Ethical Scrutiny Amid FDA Review of Genetic Engineering Trials

24 days ago

Stocks

Health Care

ntla

Intellia Therapeutics

NTLA

+0.49 (+4.27%)

11.97

USD

At close at Jul 16, 20:41 UTC